Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA, myNEO Partner to Advance Bespoke mRNA-Based Cancer Vaccines

NEW YORK – OncoDNA and myNEO said on Wednesday that they have partnered to develop personalized, mRNA-based vaccines to treat advanced cancer patients.

Within the collaboration, the Belgium-based companies will use their respective technologies —OncoDNA's whole-genome and whole-transcriptome sequencing capabilities, and myNEO's artificial intelligence and bioinformatics capabilities — to identify targetable neoantigens in individual cancer patients and design mRNA-based vaccines that instruct their immune systems to go after those targets.

Additionally, OncoDNA plans to use its blood-based next-generation sequencing test, OncoFOLLOW, to monitor patients' circulating tumor DNA after treatment with the bespoke vaccines.

"It may take years before this technology becomes a reality," Jean-Pol Detiffe, OncoDNA's founder and chief strategy and innovation officer, said in a statement. "However, the ongoing pilot tests on patients who do not respond to any therapy are showing promising results."

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.